Annovis Bio Inc
annovisbio.comAnnovis Bio (NYSE American: ANVS) is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases. The company has no approved products and generates no commercial revenue, funding operations through equity offerings, warrant exercises, and debt financings. Its sole clinical asset is buntanetap, a small-molecule drug candidate targeting Alzheimer's disease (AD) and Parkinson's disease (PD). As of the 10-K filed March 13, 2026, Annovis had completed a Phase 3 PD Trial (topline efficacy data released July 2, 2024) and was running a Phase 2/3 AD Trial initiated February 2023, with interim analyses built into each study. The company is headquartered in the United States, incorporated in Delaware, and qualifies as a smaller reporting company. Maria Maccecchini serves as President and Chief Executive Officer. Commercial revenue from buntanetap, if any, is not expected for many years pending regulatory approval.
Products & Services
Buntanetap: a single small-molecule drug candidate in clinical development for Alzheimer's disease (Phase 2/3 AD Trial initiated February 2023) and Parkinson's disease (Phase 3 PD Trial completed December 4, 2023, topline data released July 2, 2024). No approved or commercialized products as of the filing date.
Revenue Model
Pre-revenue. Cash needs are met through equity offerings, including common stock, warrants, and pre-funded warrants, as well as proceeds from warrant and stock option exercises. No product sales, licensing fees, or collaboration payments are reported in the FY2025 or FY2024 financial statements included in the filing.
Customers & Markets
No commercial customers. Target end markets, if buntanetap is approved, are patients with mild to moderate Alzheimer's disease (MMSE score 14 to 24) and early Parkinson's disease (Hoehn and Yahr stages 1, 2, or 3 with OFF times under two hours per day).
Geographic Exposure
United States primary regulatory jurisdiction (FDA). No international commercial operations described in the filing excerpts.
Financial Snapshot
Loading...
